Demographic profiles of HCT recipients in groups 1-3
| . | Group 1 (N = 178), n (%) . | Group 2 (N = 135), n (%) . | Group 3 (N = 62), n (%) . | |||
|---|---|---|---|---|---|---|
| D+/R+ . | D−/R+ . | D+/R+ . | D−/R+ . | D+/R+ . | D−/R+ . | |
| Total n | 128 (72) | 50 (28) | 98 (73) | 37 (27) | 41 (66) | 21 (34) |
| Diagnosis/diseases | ||||||
| Acute myeloid leukemia | 43 (34) | 13 (26) | 33 (34) | 9 (24) | 11 (27) | 5 (24) |
| Acute lymphoid leukemia | 22 (17) | 11 (22) | 18 (18) | 10 (27) | 12 (29) | 7 (33) |
| Chronic myeloid leukemia | 20 (16) | 6 (12) | 17 (17) | 6 (16) | 7 (17) | 3 (14) |
| Chronic lymphoid leukemia | 0 (0) | 2 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Hodgkin lymphoma | 3 (2) | 2 (4) | 3 (3) | 0 (0) | 0 (0) | 1 (5) |
| Non-Hodgkin lymphoma | 19 (15) | 7 (14) | 12 (12) | 3 (8) | 4 (10) | 0 (0) |
| Others | 21 (16) | 9 (18) | 15 (15) | 9 (24) | 7 (17) | 5 (24) |
| Source of stem cell | ||||||
| Bone marrow | 19 (15) | 11 (22) | 20 (20) | 14 (38) | 5 (12) | 4 (19) |
| Peripheral blood stem cell | 109 (85) | 39 (78) | 78 (80) | 23 (62) | 36 (88) | 17 (81) |
| Median recipient age, y | 44 y | 42 y | 42 y | 39 y | 44 y | 40 y |
| Male sex | ||||||
| Donor | 76 (59) | 31 (62) | 51 (52) | 18 (49) | 19 (46) | 10 (48) |
| Recipient | 69 (54) | 24 (48) | 47 (48) | 19 (51) | 22 (54) | 11 (52) |
| Conditioning | ||||||
| Myeloablative | 80 (63) | 30 (60) | 65 (66) | 21 (57) | 24 (59) | 14 (67) |
| Nonmyeloablative/reduced intensity | 48 (38) | 20 (40) | 33 (34) | 16 (43) | 17 (41) | 7 (33) |
| Total body irradiation | 56 (44) | 24 (48) | 45 (46) | 21 (57) | 14 (34) | 10 (48) |
| Donor type | ||||||
| URD | 31 (24) | 31 (62) | 23 (23) | 23 (62) | 11 (27) | 11 (52) |
| Sibling | 97 (76) | 19 (38) | 75 (77) | 14 (38) | 30 (73) | 10 (48) |
| Acute GVHD | ||||||
| O-I | 50 (39) | 14 (28) | 40 (41) | 11 (30) | 16 (39) | 6 (29) |
| > II | 78 (61) | 36 (72) | 58 (59) | 26 (70) | 25 (61) | 15 (71) |
| Chronic GVHD | ||||||
| None | 26 (20) | 12 (24) | 20 (20) | 10 (27) | 8 (20) | 5 (24) |
| Yes | 102 (80) | 38 (76) | 78 (80) | 27 (73) | 33 (80) | 16 (76) |
| Subjects received steroids | ||||||
| Day 90 | ||||||
| > 0 ≤ 1 mg/kg per day | 69 (54) | 30 (60) | 55 (56) | 24 (65) | 18 (44) | 15 (71) |
| > 1 mg/kg per day | 7 (5) | 5 (10) | 7 (7) | 4 (11) | 3 (7) | 2 (10) |
| Day 180 | ||||||
| > 0 ≤ 1 mg/kg per day | 59 (46) | 26 (52) | 49 (50) | 20 (54) | 18 (44) | 11 (52) |
| > 1 mg/kg per day | 10 (8) | 3 (6) | 7 (7) | 3 (8) | 4 (10) | 2 (10) |
| Day 360 | ||||||
| > 0 ≤1 mg/kg per day | 49 (38) | 20 (40) | 39 (40) | 13 (35) | 16 (39) | 8 (38) |
| > 1 mg/kg per day | 3 (2) | 2 (4) | 3 (3) | 2 (5) | 1 (2) | 0 (0) |
| CMV reactivation | ||||||
| ≥ 1 positive PCR | 73 (57) | 33 (66) | 56 (57) | 25 (68) | 17 (41) | 16 (76) |
| Median day of first positive PCR | 42.5 | 45.5 | 44 | 42 | 45 | 42 |
| Maximum viral load of PCR positives, gc/mL | 412 | 878 | 433 | 890 | 500 | 920 |
| > 1 positive BC | 49 (38) | 21 (42) | 38 (39) | 16 (43) | 12 (29) | 10 (48) |
| Any GCV treatment | 56 (44) | 28 (56) | 42 (43) | 23 (62) | 14 (34) | 15 (71) |
| Prolonged and/or recurrent GCV treatment | 18 (14) | 16 (32) | 12 (12) | 12 (32) | 5 (12) | 8 (38) |
| CMV disease | 7 (5) | 4 (8) | 5 (5) | 3 (8) | 2 (5) | 1 (5) |
| . | Group 1 (N = 178), n (%) . | Group 2 (N = 135), n (%) . | Group 3 (N = 62), n (%) . | |||
|---|---|---|---|---|---|---|
| D+/R+ . | D−/R+ . | D+/R+ . | D−/R+ . | D+/R+ . | D−/R+ . | |
| Total n | 128 (72) | 50 (28) | 98 (73) | 37 (27) | 41 (66) | 21 (34) |
| Diagnosis/diseases | ||||||
| Acute myeloid leukemia | 43 (34) | 13 (26) | 33 (34) | 9 (24) | 11 (27) | 5 (24) |
| Acute lymphoid leukemia | 22 (17) | 11 (22) | 18 (18) | 10 (27) | 12 (29) | 7 (33) |
| Chronic myeloid leukemia | 20 (16) | 6 (12) | 17 (17) | 6 (16) | 7 (17) | 3 (14) |
| Chronic lymphoid leukemia | 0 (0) | 2 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Hodgkin lymphoma | 3 (2) | 2 (4) | 3 (3) | 0 (0) | 0 (0) | 1 (5) |
| Non-Hodgkin lymphoma | 19 (15) | 7 (14) | 12 (12) | 3 (8) | 4 (10) | 0 (0) |
| Others | 21 (16) | 9 (18) | 15 (15) | 9 (24) | 7 (17) | 5 (24) |
| Source of stem cell | ||||||
| Bone marrow | 19 (15) | 11 (22) | 20 (20) | 14 (38) | 5 (12) | 4 (19) |
| Peripheral blood stem cell | 109 (85) | 39 (78) | 78 (80) | 23 (62) | 36 (88) | 17 (81) |
| Median recipient age, y | 44 y | 42 y | 42 y | 39 y | 44 y | 40 y |
| Male sex | ||||||
| Donor | 76 (59) | 31 (62) | 51 (52) | 18 (49) | 19 (46) | 10 (48) |
| Recipient | 69 (54) | 24 (48) | 47 (48) | 19 (51) | 22 (54) | 11 (52) |
| Conditioning | ||||||
| Myeloablative | 80 (63) | 30 (60) | 65 (66) | 21 (57) | 24 (59) | 14 (67) |
| Nonmyeloablative/reduced intensity | 48 (38) | 20 (40) | 33 (34) | 16 (43) | 17 (41) | 7 (33) |
| Total body irradiation | 56 (44) | 24 (48) | 45 (46) | 21 (57) | 14 (34) | 10 (48) |
| Donor type | ||||||
| URD | 31 (24) | 31 (62) | 23 (23) | 23 (62) | 11 (27) | 11 (52) |
| Sibling | 97 (76) | 19 (38) | 75 (77) | 14 (38) | 30 (73) | 10 (48) |
| Acute GVHD | ||||||
| O-I | 50 (39) | 14 (28) | 40 (41) | 11 (30) | 16 (39) | 6 (29) |
| > II | 78 (61) | 36 (72) | 58 (59) | 26 (70) | 25 (61) | 15 (71) |
| Chronic GVHD | ||||||
| None | 26 (20) | 12 (24) | 20 (20) | 10 (27) | 8 (20) | 5 (24) |
| Yes | 102 (80) | 38 (76) | 78 (80) | 27 (73) | 33 (80) | 16 (76) |
| Subjects received steroids | ||||||
| Day 90 | ||||||
| > 0 ≤ 1 mg/kg per day | 69 (54) | 30 (60) | 55 (56) | 24 (65) | 18 (44) | 15 (71) |
| > 1 mg/kg per day | 7 (5) | 5 (10) | 7 (7) | 4 (11) | 3 (7) | 2 (10) |
| Day 180 | ||||||
| > 0 ≤ 1 mg/kg per day | 59 (46) | 26 (52) | 49 (50) | 20 (54) | 18 (44) | 11 (52) |
| > 1 mg/kg per day | 10 (8) | 3 (6) | 7 (7) | 3 (8) | 4 (10) | 2 (10) |
| Day 360 | ||||||
| > 0 ≤1 mg/kg per day | 49 (38) | 20 (40) | 39 (40) | 13 (35) | 16 (39) | 8 (38) |
| > 1 mg/kg per day | 3 (2) | 2 (4) | 3 (3) | 2 (5) | 1 (2) | 0 (0) |
| CMV reactivation | ||||||
| ≥ 1 positive PCR | 73 (57) | 33 (66) | 56 (57) | 25 (68) | 17 (41) | 16 (76) |
| Median day of first positive PCR | 42.5 | 45.5 | 44 | 42 | 45 | 42 |
| Maximum viral load of PCR positives, gc/mL | 412 | 878 | 433 | 890 | 500 | 920 |
| > 1 positive BC | 49 (38) | 21 (42) | 38 (39) | 16 (43) | 12 (29) | 10 (48) |
| Any GCV treatment | 56 (44) | 28 (56) | 42 (43) | 23 (62) | 14 (34) | 15 (71) |
| Prolonged and/or recurrent GCV treatment | 18 (14) | 16 (32) | 12 (12) | 12 (32) | 5 (12) | 8 (38) |
| CMV disease | 7 (5) | 4 (8) | 5 (5) | 3 (8) | 2 (5) | 1 (5) |
Distribution of HCT recipients in groups 1-3 by category of pretransplantation factors including underlying diagnosis, stem cell source, recipient age, sex, conditioning regimen, and donor type. Posttransplantation outcomes are tabulated for groups 1-3 including acute and chronic GVHD, steroid usage above and below 1 mg/kg for 3 time points, CMV reactivation defined by PCR, blood culture (BC), GCV treatment, and diagnosis of CMV disease. GVHD grades are based on the Keystone scale. HCT patient groups 1-3 are defined in “Prospective study subjects.”
URD indicates 6/6 antigen-matched unrelated donor; and gc, genome copies.